Q-omics provides the consensus-scored STIMATE-MUSTN1 profile across patient tissues and cancer cell-line models. STIMATE-MUSTN1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STIMATE-MUSTN1 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, STIMATE-MUSTN1 RNA expression shows 17,764 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, LIHC, and UVM as cancer lineages where STIMATE-MUSTN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STIMATE-MUSTN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STIMATE-MUSTN1 survival associations across molecular data types. STIMATE-MUSTN1 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STIMATE-MUSTN1 RNA expression–survival associations across cancer types. High STIMATE-MUSTN1 expression shows unfavorable associations in KIRC, ACC, LGG and OV, but favorable associations in HNSC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STIMATE-MUSTN1 RNA expression.
This table summarizes STIMATE-MUSTN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for STIMATE-MUSTN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STIMATE-MUSTN1 shows lower tumor expression in LUSC, LUAD, BRCA, THCA and UCEC and higher tumor expression in LIHC. The LIHC box plot shows higher STIMATE-MUSTN1 RNA expression in tumor versus normal tissue (log2 FC = +0.163, t-test p < 0.001).
This table shows molecular features associated with STIMATE-MUSTN1 in patient tissues and cancer cell lines. In patient samples, STIMATE-MUSTN1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STIMATE-MUSTN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
